Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: Audit of Veterinary Drug Retail Sales in Russia (August 2020)

Friday, September 18, 2020

Between January and August 2020, the sales of veterinary drugs in the retail market amounted to RUB 14.3 bln (retail prices, VAT included), which is in monetary terms (rubles) hardly a hundredth of a percent higher than in 2019. The volume in physical terms is 125.1 bln minimum dosage units (MDU), which is 1.7% lower than in 2019. These unimpressive results are mostly due to low demand in August 2020, when the volume of consumption dropped by 6.3% in monetary and by 6.7% in physical terms.

Despite the low demand, summer 2020 did not deviate from the seasonal trends much: the spring peak was followed by a calm period, which was replaced by another peak between August and September. The drop in consumption is largely due to the consequences of the coronavirus epidemic. Since the borders for most traditional tourist destinations were closed, domestic tourism skyrocketed in August. Before the start of the school year, Russians were trying to catch up on what they missed during self-isolation, so that consumption priorities shifted from the veterinary market. These trends resulted in a noticeable change in the competitive environment, with Russian companies losing first place in the sales volume in monetary terms between January and August 2020 to American companies. While the sales of the former have dropped by 3%, those of the latter have increased by 8%.

Zoetis has the best sales dynamics among the American companies (+19% in monetary terms). Their vaccine for dogs Vanguard (sales grown by 4 times), insectoacaricide Simparica (+58%) and antipruritic Apoquel (+45%) contributed to the dynamics the most. Zoetis is followed by MSD (+8%) with their Bravecto (+16%) and porcine insulin preparation Caninsulin (+21%).

Agrobioprom has the highest dynamics among the Russian companies (+49%), with their Pchelodar line products, in particular, insectoacaricides Pchelodar Binakar, contributing to the dynamics. Ekoprom/Neoterica also has good dynamics (+8%). The sales of their antiparasitic products Neoterica Protecto have increased by 500 times. However, the products were launched as recently as in August 2019, which speaks of the low base effect.

Volume of the Russian retail market of veterinary drugs in monetary (consumer prices, VAT included) and physical (MDU) terms (January 2019 – August 2020)